Skip to main content

Deferoxamine Injection Shortage

Last Updated: August 16, 2021
Status: Resolved

Products Affected - Description
    • Deferoxamine injection, Pfizer, 500 mg, vial, 4 count, NDC 00409-2336-10 - discontinued
Reason for the Shortage
    • Fresenius Kabi had deferoxamine on shortage due to increased demand.
    • Pfizer had deferoxamine on shortage due to manufacturing delays. The 500 mg vials were discontinued in April 2021.
    • Novartis has Desferal available.
    • Almaject did not provide a reason for the shortage. Almaject discontinued the 500 mg vials in late-2019.
    • Apo-Pharma launched deferoxamine injection in mid-2018.
Available Products
    • Desferal injection, Novartis, 500 mg, vial, 4 count, NDC 00078-0467-91
    • Deferoxamine injection, Almaject, 2 gram, vial, 1 count, NDC 47781-0624-07
    • Deferoxamine injection, Apo-Pharma, 2 gram, vial, 4 count, NDC 52609-4504-06
    • Deferoxamine injection, Apo-Pharma, 500 mg, vial, 4 count, NDC 52609-4505-06
    • Deferoxamine injection, Fresenius Kabi, 2 gram, vial, 1 count, NDC 63323-0599-30
    • Deferoxamine injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0597-10
    • Deferoxamine injection, Pfizer, 2 gram, vial, 4 count, NDC 00409-2337-25

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated August 16, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 7, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer